Miiskin App First of Its Kind Recommended by GPs on EMIS App Library
Denmark (May 26, 2020) – Skin checking app Miiskin, which supports the work of the British Skin Foundation, is the first digital health app of its kind to be listed on the EMIS App Library and recommended by GPs and other primary care clinicians.
The app, which was developed to encourage people to be more aware of changes to their skin, has also gone live on the NHS Apps Library – becoming one of fewer than 100 apps to be listed.
EMIS Health and IQVIA, a global leader in human data science, have collaborated to enable 58% of GPs in England to electronically recommend Miiskin. The app, which recently made artificial intelligence (AI) skin mapping available via consumer technology, can be recommended to patients using EMIS App Library by AppScript®.
EMIS App Library provides clinicians with a list of high quality digital health apps that they can electronically recommend to patients directly from their existing EMIS Web workflows, enabling patients to access the right support for their specific needs. All the apps in the library have been reviewed using NHS Digital’s Digital Assessment Questions (DAQ) framework or have been recommended or commissioned by local NHS authorities. The DAQ framework, which is also used for populating apps in the NHS Apps Library, includes strict criteria against:
- Effectiveness
- Clinical safety
- Data protection
- Security
- Usability and accessibility
- Interoperability
- Technical stability
When GPs recommend apps to patients using EMIS App Library, they receive a download link via text or email. So far, more than 60% of patients recommended an app via the platform click through to install or enroll for the app.
Miiskin was developed to help people digitally track changes to existing moles, as well as new moles and marks using AI skin mapping to help detect early warning signs of skin cancer. Since it was launched, the app has had 500,000 downloads globally and 65,000 in the UK. It does not try to diagnose skin cancer or tell users that they are at risk or not. Those who do spot changes are encouraged to seek advice from their GP or specialist.
The app is supported by dermatologists. Ninety-three percent of dermatologists in the Skin Health Alliance 2019 Survey said patients’ use of photographic records of moles and wider areas of the skin was a good way of monitoring the skin and moles for changes.
“We are delighted that Miiskin has been listed on the EMIS App Library for GP referral, as well as the NHS Apps Library.
The app enables users to track their skin and present photographic evidence to clinicians if they notice concerning changes. Unlike other apps, Miiskin doesn’t aim to encourage patients to self-diagnose.”
– Jon Friis, founder and CEO of Miiskin.
Thirty-six-year old Emma Hawke from Eastleigh, near Southampton, started using the Miiskin app following her diagnosis of skin cancer to keep track of changes to her skin. She said:
“Between check-ups with my dermatologist, they leave it up to you to monitor your moles and recommended taking photos of your skin to see if there have been any changes. I had so many photos in my camera roll that they just got lost in there.
Using the Miiskin app is so much easier, as the photos are kept together so you can easily compare your moles. The comparison photographs can be taken with you to the dermatologist so they can easily see any changes.”
– Emma Hawke, user of the Miiskin app.
“We believe that high-quality digital health apps work best for all parties when recommended by clinicians using workflow-integrated tools such as EMIS App Library by AppScript®.
We’re highly selective in which apps are included within the library. We welcome Miiskin in joining us in our mission to help clinicians connect the right patients to the right digital therapeutics at the right time.”
– Brian Clancy, Associate Director, IQVIA and responsible for AppScript®
“IQVIA is proud to enable the EMIS App Library through AppScript® and this work with Miiskin demonstrates again the growing importance of apps to enable new and improved models of care, in line with the Government’s NHS Digital Plan.”
– Tim Sheppard, General Manager and Senior Vice President, Northern Europe, IQVIA
“There are thousands of apps available and it can be overwhelming for both clinicians and patients to know which ones to trust. The EMIS App Library helps clinicians guide their patients to high quality, critically validated apps through EMIS Web. This helps patients become more involved in their care and provide better outcomes.”
– Suzy Foster, EMIS Health CEO
About Miiskin
Miiskin was founded in Denmark by Jon Friis, who needed a better way to track the moles on his partner Rikke’s back to check for signs of Melanoma. When Jon was told by the doctor that current best practice was using pen and paper, he couldn’t help thinking that technology could simplify and improve this process.
The Miiskin app has already received 500,000 downloads and hundreds of positive messages from users around the world.
Crucially, the app does not try to diagnose skin cancer or tell users that they are at risk or not. The detection of skin cancer is complex and should only be undertaken by qualified doctors – not apps. Miiskin helps you keep a regular eye on your skin, so you can seek medical help if you spot concerning changes.
Miiskin has supported the work of the British Skin Foundation since 2017 and works with the charity to raise awareness of the importance of people checking their skin for changes.
Miiskin was the first app to be listed on the NHS App Library that can help people with spotting the early signs of skin cancer.
The app successfully passed an assessment based on the Digital Assessment Questions (DAQs) maintained by key NHS stakeholders and has been listed on the NHS Apps Library since February 2020. While there are hundreds of thousands of digital health apps available globally, fewer than 100 have successfully accomplished listing on NHS Apps Library given the high-quality bar required to be met.
miiskin.com
www.nhs.uk
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology, and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com
www.iqvia.com
About EMIS Group
EMIS Group is the UK leader in connected healthcare software and services. Its solutions are widely used across every major UK healthcare setting from primary, community & acute care, to high street pharmacies and specialist care services. EMIS Group helps healthcare professionals in over 10,000 organisations share vital information, facilitating better, more efficient healthcare and supporting longer and healthier lives.
EMIS Group serves the following healthcare markets under the EMIS Health brand:
- Primary, Community & Acute Care, as the UK leader in clinical management systems for healthcare providers and commissioners. EMIS Health products, including the flagship EMIS Web, hold over 40 million patient records and are used by more than 100,000 professionals in nearly 6,000 healthcare organisations.
- Community Pharmacy, with the UK’s single most used integrated community pharmacy and retail system.
- Specialist Care, as England’s leading provider of diabetic eye screening software and other ophthalmology-related solutions.
Privacy Statement
EMIS App Library by AppScript® was built with rigorous privacy and security features to safeguard sensitive information. Its apps have either been listed on the NHS Apps Library, have gone through NHS Digital’s Digital Assessment Questionnaire, or have otherwise been authorised for listing on EMIS App Library by relevant NHS authorities.